{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-008294","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2025-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.551340+00:00","generated_at":"2026-05-20T04:17:17.099272+00:00","sec_items":["5.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Coherus BioSciences renames to Coherus Oncology, sharpens focus on cancer immunotherapy","bullets":["Name change to Coherus Oncology, Inc. effective May 29, 2025; stock ticker CHRS unchanged.","Company now exclusively focused on proprietary immuno-oncology medicines; pipeline includes LOQTORZI, CHS-114, and casdozokitug.","LOQTORZI is a next-gen PD-1 inhibitor approved for nasopharyngeal carcinoma; CHS-114 is a CCR8 antibody in Phase 1b.","Casdozokitug, an IL-27 antagonist, is in a randomized Phase 2 study for first-line advanced metastatic HCC.","Board and scientific advisors include leaders from Cancer Research Institute, MSKCC, and HHMI."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-008294","json":"https://secwatch.observer/filing/0001558370-25-008294.json","markdown":"https://secwatch.observer/filing/0001558370-25-008294.md","text":"https://secwatch.observer/filing/0001558370-25-008294.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000155837025008294/0001558370-25-008294-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000155837025008294/chrs-20250529x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T04:17:17.099272+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}